No abstract

Introduction: Risankizumab has demonstrated efficacy and safety in phase 3 studies in patients with moderate to severe plaque psoriasis. This randomized clinical trial assessed the efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis in the Russian Federation. Methods: Patients with moderate to severe plaque psoriasis were randomized 4:1 to 16 weeks of double-blind treatment with risankizumab 150 mg or placebo (period A; dosing at baseline and week 4) followed by an open-label extension (period B) during which all patients received risankizumab 150 mg at weeks 16, 28, and 40 and were followed up to week 52. The primary study endpoint was the proportion of patients achieving C 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 16, and secondary endpoints included Static Physician's Global Assessment scores and the Dermatology Life Quality Index. Treatmentemergent adverse events were monitored throughout the two study periods. Results: Of the 50 patients who entered period A, 41 were randomized to receive risankizumab and 9 to receive placebo. Forty-eight patients entered period B, and 47 completed the study. A significantly larger proportion of risankizumabtreated patients achieved PASI 90 at week 16 compared with placebo-treated patients [response rate difference: 38.8% (95% CI 7.8-69.7%; P = 0.035)]. Consistently higher proportions of risankizumab-treated patients achieved secondary endpoints compared with the placebo-treated patients. Safety profiles wereThe affiliation shown for Maureen Kelly was her affiliation at the time of this research.

Актуальность данного обзора обусловлена про-шедшим 75-летним юбилеем открытия лактоферри-на (ЛФ) [1], стремлением подвести некоторые итоги собственных 40-летних исследований этого белка [2,3] и желанием привлечь внимание специалистов, ра-ботающих в репродуктологии, -от андрологов до эмбриологов -к исследованию ЛФ. Этому белку ежегодно посвящены сотни работ в мировой литера-туре, а в России уделяется незаслуженно мало вни-мания.ЛФ является членом обширной семьи трансфер-рина, вместе с трансферрином, овотрансферрином и меланотрансферрином, ингибиторами карбоанги-дразы и другими полипептидами [4]. ЛФ вырабаты-вается эпителиальными клетками слизистых оболо-чек у различных видов млекопитающих, включая человека, коров, коз, лошадей, собак и грызунов, а также обнаружен у рыб [5]. Этот многофункциональ-ный гликопротеин обнаруживается в слизистых вы-делениях, в том числе слезах, слюне, вагинальной жидкости, поте, сперме [6,7], носовом и бронхиаль-ном секретах, желчи, моче [5], молоке и молозиве [6].С 1969 г. известно, что ЛФ продуцируется клет-ками миелоидного ряда в костном мозге и затем ло-кализуется во вторичных гранулах зернистых ней-e-mail: chimnik@mail.ru doi: 10.17116/repro201521625-30 Лактоферрин и его роль в репродукции (обзор литературы)Д.м.н., проф. А.А. НИКОЛАЕВ, д.м.н., с.н.с. А.Е. СУХАРЕВ ГБОУ ВПО «Астраханский государственный медицинский университет» Минздрава России, Астрахань, Россия, 414000Обзор современного состояния знаний о строении, свойствах железосодержащего белка лактоферрина (ЛФ). Рассмотрены вопросы, касающиеся строения, синтеза, функции, продукции и уровня лактоферрина в различных биологических жидкостях организма человека. Освещены работы, оценивающие патогенетическую, диагностическую и прогностическую значимость этого белка при нарушениях репродуктивной функции у женщин и мужчин. Overview of data about the structure, properties of the iron-containing protein lactoferrin (LF) is presented. Pathogenetic, diagnostic and prognostic importance of this protein in the reproductive disorders in women and men is discussed.

INTRODUCTION. Coronary artery bypass surgery is the most popular method of surgical treatment of patients with chronic heart failure of ischemic origin. Modern direction of developing the cardiac surgery in treating patients with chronic heart failure of ischemic origin is «off-pump» techniques. However, the high risk of emergency conversion to «on pump» reduce the availability for using «off pump» techniques with this kind of patients. Preoperative risk factors for unplanned conversion to cardiopulmonary bypass have not been studied. The OBJECTIVE was to determine preoperative risk factors of urgent conversion to bypass in patients with congestive ischemic heart failure during off-pump coronary artery bypass grafting. METHODS AND MATERIALS. The results of 44 coronary artery bypass grafting (CABG) off-pump procedures in patients with ischemic cardiomyopathy were retrospectively analyzed. Emergent conversion to artificial circulation was needed due to acute heart failure in 8 (18 %) patients. All patients were divided into 2 groups depending on the necessity for emergency using the cardiopulmonary bypass. Then the patients' preoperative status was analyzed. RESULTS. We determined that the risk factors of emergent conversion to cardiopulmonary bypass were observed in the following cases: patients after 70 years old with a combined left main coronary artery lesion and right coronary artery occlusion; left ventricle end-diastolic size more than 70 mm; mild mitral insufficiency; the presence of atrial or ventricle rhythm disturbances; EuroSCORE logistic score more than 4.9 %. CONCLUSION. The identified risk factors allow to minimize the risk of urgent conversion to bypass circulation during off-pump myocardial revascularization in patients with congestive ischemic heart failure. When these risk factors are present, it is recommended to use on-pump or on-pump beating heart techniques of coronary artery bypass grafting in these patients.